<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3865347</article-id><article-id pub-id-type="pmid">24348903</article-id><article-id pub-id-type="publisher-id">PONE-D-13-21696</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0079843</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma</article-title><alt-title alt-title-type="running-head">p53 Drug Response Signature in Neuroblastoma</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Barbieri</surname><given-names>Eveline</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>De Preter</surname><given-names>Katleen</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Capasso</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Johansson</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Man</surname><given-names>Tsz-Kwong</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Zaowen</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Stowers</surname><given-names>Paris</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tonini</surname><given-names>Gian Paolo</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Speleman</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shohet</surname><given-names>Jason M.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Texas Children&#x02019;s Cancer Center and Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Center for Medical Genetics, Ghent University, Ghent, Belgium</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>CEINGE Biotecnologie Avanzate, Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Pediatric Research Institute, University of Padua, Padua, Italy</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Chesler</surname><given-names>Louis</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Institute of Cancer Research: Royal Cancer Hospital, United Kingdom</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>jmshohet@txch.org</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: EB JS FS. Performed the experiments: EB KDP ZC PS JS. Analyzed the data: KDP MC PJ TKM JS. Contributed reagents/materials/analysis tools: GPT. Wrote the paper: EB JS FS KDP MC.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>11</month><year>2013</year></pub-date><pub-date pub-type="ecorrected"><day>16</day><month>12</month><year>2013</year></pub-date><volume>8</volume><issue>11</issue><elocation-id>e79843</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>25</day><month>9</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Barbieri et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Barbieri et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>Chemotherapy induces apoptosis and tumor regression primarily through activation of p53-mediated transcription. Neuroblastoma is a p53 wild type malignancy at diagnosis and repression of p53 signaling plays an important role in its pathogenesis. Recently developed small molecule inhibitors of the MDM2-p53 interaction are able to overcome this repression and potently activate p53 dependent apoptosis in malignancies with intact p53 downstream signaling. We used the small molecule MDM2 inhibitor, Nutlin-3a, to determine the p53 drug response signature in neuroblastoma cells. In addition to p53 mediated apoptotic signatures, GSEA and pathway analysis identified a set of p53-repressed genes that were reciprocally over-expressed in neuroblastoma patients with the worst overall outcome in multiple clinical cohorts. Multifactorial regression analysis identified a subset of four genes (CHAF1A, RRM2, MCM3, and MCM6) whose expression together strongly predicted overall and event-free survival (p&#x0003c;0.0001). The expression of these four genes was then validated by quantitative PCR in a large independent clinical cohort. Our findings further support the concept that oncogene-driven transcriptional networks opposing p53 activation are essential for the aggressive behavior and poor response to therapy of high-risk neuroblastoma.</p></abstract><funding-group><funding-statement>This work was supported by Ale&#x02019;s Lemonade Stand Foundation (EB, JMS), the Children&#x02019;s Cancer Research Foundation (EB) and a Research Scholar Grant from the American Cancer Society (JMS). KDP is supported by the Flemish Fund for Scientific Research. MC is supported by Associazione Italiana per la Lotta al Neuroblastoma and MIUR - FIRB Ricerca in Futuro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Neuroblastoma (NB), an embryonal tumor arising in tissues of the sympathetic nervous system, is the most common cancer diagnosed during the first year of life and accounts for 13% of all deaths due to childhood malignancies. Despite intense multimodality therapy, at least half of high-risk patients will experience relapse that is almost always fatal <xref rid="pone.0079843-Maris1" ref-type="bibr">[1]</xref>. Much of the difficulty in devising effective therapies for this latter group of patients lies in the heterogeneity of their disease, which can be attributed largely to the interaction of multiple genetic factors, including both sequence and copy number variants <xref rid="pone.0079843-Speleman1" ref-type="bibr">[2]</xref>, <xref rid="pone.0079843-Cohn1" ref-type="bibr">[3]</xref>. Amplification of the <italic>MYCN</italic> gene has emerged as one of the most reliable indicators of aggressive and treatment-resistant neuroblastoma, yet 30% to 40% of high-risk tumors lack this feature <xref rid="pone.0079843-Maris1" ref-type="bibr">[1]</xref>. Genomic studies, including massively parallel DNA sequencing, have failed to reveal additional recurrent molecular lesions in neuroblastoma, with the exception of ALK mutations found in a small percentage of high-risk tumors <xref rid="pone.0079843-JanoueixLerosey1" ref-type="bibr">[4]</xref>, <xref rid="pone.0079843-Molenaar1" ref-type="bibr">[5]</xref>, <xref rid="pone.0079843-Chen1" ref-type="bibr">[6]</xref>.</p><p>A number of previous observations confirm that wild-type p53 alleles are present in the vast majority of cases of newly diagnosed neuroblastoma, but that p53/MDM2/ARF responses to chemotherapy are repressed, in part due to unscheduled inhibition of p53 by MDM2 <xref rid="pone.0079843-Carr1" ref-type="bibr">[7]</xref>, <xref rid="pone.0079843-CarrWilkinson1" ref-type="bibr">[8]</xref>, <xref rid="pone.0079843-Chen2" ref-type="bibr">[9]</xref>. This suggests that down- regulation of the p53 axis may underlie the treatment resistance typically seen in high-risk neuroblastoma. To further investigate downstream p53-effector genes contributing to this cancer phenotype, we used Nutlin-3a, an MDM2 antagonist, which specifically activates p53 leading to apoptosis and tumor regression of both chemosensitive and chemoresistant neuroblastoma cell lines <xref rid="pone.0079843-Vassilev1" ref-type="bibr">[10]</xref>, <xref rid="pone.0079843-Barbieri1" ref-type="bibr">[11]</xref>, <xref rid="pone.0079843-VanMaerken1" ref-type="bibr">[12]</xref>. We compared gene expression profiles before and after Nutlin treatment and used bioinformatic approaches to identify p53 drug response genes whose aberrant expression in high-risk disease may limit p53 activation in response to genotoxic chemotherapy, increasing the risk of disease progression and relapse. With this approach we identified four genes that are highly over expressed in high-risk neuroblastoma (CHAF1A, RRM2, MCM3, and MCM6) whose expression strongly correlates with poor outcomes. Importantly, these genes are all directly repressed by Nutlin-3a-induced p53 activation, are markers of aggressive disease in other cancers, and have functions related to tumorigenesis and aberrant DNA replication and transcription <xref rid="pone.0079843-Spurgers1" ref-type="bibr">[13]</xref>, <xref rid="pone.0079843-Hoek1" ref-type="bibr">[14]</xref>, <xref rid="pone.0079843-Cerqueira1" ref-type="bibr">[15]</xref>, <xref rid="pone.0079843-Koppen1" ref-type="bibr">[16]</xref>.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Tissue Culture</title><p>JF (ATCC), IMR32 (ATCC), LAN5 (LS Metelitsa, Houston TX), and LAN1 (ATCC) human NB lines were maintained in RPMI 1640; human colorectal cancer cell line, HCT 116 (ATCC), and human breast cancer cell line, MCF7 (ATCC), in McCoy&#x02019;s 5A and DMEM plus 1% insulin respectively; human osteosarcoma line, SJSA-1 (ATCC), in RPMI 1640 medium with 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate; primary neuroblastoma lines (p202, p218, pH) (Texas Children&#x02019;s Cancer Center, Houston, TX) and CHLA255 line (LS Metelitsa) in IMDM with 20% FBS and 0.1% ITS. The p53-mutant NB line, SJ3-12 (21 amino acids deletion in the DNA binding domain), was provided by Dr. Dirk Geerts, University of Amsterdam, the Netherlands and used as control <xref rid="pone.0079843-Chen2" ref-type="bibr">[9]</xref>. Nutlin-3a (provided by Dr. Vassilev - Roche, Nutley, NJ) was used at the concentration of 10 uM (in DMSO).</p></sec><sec id="s2b"><title>Oligonucleotide Microarray Data Analysis</title><p>Total RNA was isolated using RNAeasy kit (Quiagen) from the early passage cell line p202 at the 3, 8 and 16 hrs time points. Using Affymetrix&#x02122; U133a microarrays, we compared expression profiles of Nutlin-3a and Nutlin-3b (inactive enantiomer) treated p202 primary NB cells over time points. Two biological replicates were carried out for time-series experiments. Microarray data were analyzed by an ANOVA time series model using FDR &#x0003c; 0.1 as a statistical cutoff. Class and time comparison analysis identified probe sets differentially expressed between Nutlin treatments (class effect) and time points (time effect). Data were clustered using Cluster 3.0, with centered correlation as distance measure for both genes and arrays.</p></sec><sec id="s2c"><title>Gene Set Enrichment Analysis (GSEA)</title><p>For each time point, genes were ranked with respect to the average expression change upon Nutlin-3a treatment. GSEA was then performed for each of the three time points using gene permutation alternative. Enrichment analysis was done with default parameter settings. An enrichment score was calculated for each gene set (KS-statistics) reflecting if the genes in the particular gene set appeared in the top (positive score), in the bottom (negative score), or were randomly distributed (close to zero score). These scores were compared with scores calculated from 1,000 randomly permuted gene lists, in order to calculate false discovery rates (FDR) (cutoff at FDR&#x0200a;=&#x0200a;0.05) <xref rid="pone.0079843-Subramanian1" ref-type="bibr">[17]</xref>.</p></sec><sec id="s2d"><title>Clinical Patient Cohort Groups</title><p>1. Oberthuer set (n&#x0200a;=&#x0200a; 251), discovery set 1. 251 NB tumors profiled on custom Agilent 44k arrays and downloaded from ArrayExpress EBI (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/arrayexpress">http://www.ebi.ac.uk/arrayexpress</ext-link>) (E-TABM-38) <xref rid="pone.0079843-Oberthuer1" ref-type="bibr">[18]</xref>.</p><p>2. Neuroblastoma Research Consortium (NRC) set (n&#x0200a;=&#x0200a; 101), discovery set 2. 101 NB tumors profiled on the Human Exon 1.0 ST Affymetrix array <xref rid="pone.0079843-DePreter1" ref-type="bibr">[19]</xref>.</p><p>3. Wang set (n&#x0200a;=&#x0200a; 99), discovery set 3. 99 NB tumors profiled on Affymetrix U95Av2 array (Gene Expression Omnibus -GEO- database, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>) <xref rid="pone.0079843-Wang1" ref-type="bibr">[20]</xref>.</p><p>4. Versteeg set (n&#x0200a;=&#x0200a; 88), discovery set 4. 88 NB tumors profiled on the Affymetrix HGU133plus2.0 platform (R2 database, microarray analysis and visualization platform, <ext-link ext-link-type="uri" xlink:href="http://r2.amc.nl">http://r2.amc.nl</ext-link>).</p><p>5. Khan set (n&#x0200a;=&#x0200a; 56), discovery set 5. 56 primary NB tumors (Oncogenomics, <ext-link ext-link-type="uri" xlink:href="http://home.ccr.cancer.gov/oncology/oncogenomics">http://home.ccr.cancer.gov/oncology/oncogenomics</ext-link>) <xref rid="pone.0079843-Wei1" ref-type="bibr">[21]</xref>.</p><p>6. Vermeulen set (n&#x0200a;=&#x0200a;348), discovery set 6. 348 NB tumors taken from the International Society of Pediatric Oncology, European Neuroblastoma Group (SIOPEN) and from the Gesellschaft fuer Paediatrische Onkologie und Haematologie (GPOH). Patients were only included if primary untreated tumor RNA samples were available and of sufficient quality <xref rid="pone.0079843-Vermeulen1" ref-type="bibr">[22]</xref>. Expression of the four gene signature was evaluated in this cohort using real-time quantitative PCR.</p></sec><sec id="s2e"><title>Data Analysis and Statistics of Gene Expression in Neuroblastoma Tumors</title><p>Gene expression data were evaluated according to methods previously developed for assessment of gene/survival outcomes <xref rid="pone.0079843-DePreter1" ref-type="bibr">[19]</xref>, <xref rid="pone.0079843-Vermeulen1" ref-type="bibr">[22]</xref>. Signature scores of the 25- or 4-gene lists were obtained by calculating the sum of the ranks of the (standardized) expression values of the 25 or 4 genes across the different samples in a dataset. Expression of the gene set correlates with signature score <xref rid="pone.0079843-Fredlund1" ref-type="bibr">[23]</xref>. Alternatively, we performed Prediction Analysis for Microarrays (PAM) classification using the MCR estimate R package. Kaplan-Meier survival analysis and log-rank analysis were carried out using the R survival package (R version 10.1). Multivariate logistic regression analyses were done using SPSS (version 16). Currently used risk factors such as age at diagnosis (&#x02265;12 months vs. &#x0003c;12 months), International Neuroblastoma Staging System (INSS) stage (stage 4 vs. other stages), and <italic>MYCN</italic> status (amplified vs. non-amplified) were tested. GEMS algorithm <xref rid="pone.0079843-Statnikov1" ref-type="bibr">[24]</xref> was used to construct support vector machine (SVM) predictors using 20-fold cross-validation for each clinical factor: death event (DE), relapse event (RE), and INSS stage. The efficiency of the predictor was estimated by a receiver operator characteristic (ROC) analysis and recorded as the area under the curve (AUC).</p></sec><sec id="s2f"><title>Real-Time qPCR</title><p>A qPCR assay was designed for each of the four genes and five reference genes by PrimerDesign and went through an extensive in silico validated analysis using BLAST and BiSearch specificity, amplicon secondary structure, SNP presence, and splice variant analysis. The mean amplification efficiency was 98%. Primer design and real time quantitative PCR analysis were performed as described <xref rid="pone.0079843-Vermeulen1" ref-type="bibr">[22]</xref>: primer sequences are available in RTPrimerDB <xref rid="pone.0079843-Lefever1" ref-type="bibr">[25]</xref>: CHAF1A (ID&#x0200a;=&#x0200a;8273), RRM2 (ID&#x0200a;=&#x0200a;8270), MCM6 (ID&#x0200a;=&#x0200a;8271), MCM3 (ID&#x0200a;=&#x0200a;8272) and reference genes: HPRT1 (ID&#x0200a;=&#x0200a;5), SDHA (ID&#x0200a;=&#x0200a;7), UBC (ID&#x0200a;=&#x0200a;8), and HMBS (ID&#x0200a;=&#x0200a;4). Data handling and calculations (normalization, rescaling, inter-run calibration, and error propagation) were done in qBasePlus version 1&#x000b7;1 (<ext-link ext-link-type="uri" xlink:href="http://www.qbaseplus.com">http://www.qbaseplus.com</ext-link>) <xref rid="pone.0079843-Hellemans1" ref-type="bibr">[26]</xref>
<xref rid="pone.0079843-Lefever2" ref-type="bibr">[27]</xref>.</p></sec><sec id="s2g"><title>Plasmids and Antibodies</title><p>ShRNA mediated p53 knockdown: To knock down p53 expression, second generation lentiviruses expressing shp53 and shLuc control were used as described <xref rid="pone.0079843-Budanov1" ref-type="bibr">[28]</xref>. Briefly, 293T cells were transfected with pLSLPw construct along with packaging plasmids, pVSVG and pLV-CMV-delta 8.2 by using lipofectamine. Virus-containing supernatants were collected at 48 and 72 hours and neuroblastoma cells transduced in the presence of 8 mg/ml polybrene (Sigma).</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Transcriptional profiling of p53 response in neuroblastoma identifies important genes with respect to outcome</title><p>To initially assess the p53-dependent response we used the MDM2 inhibitor Nutlin-3a to stabilize p53 in a panel of primary (p202, p218, and H) and established neuroblastoma lines and tested its ability to induce apoptosis in neuroblastoma cells compared to other solid tumors. At 24 hours all neuroblastoma lines showed a higher percentage of apoptosis compared to non-neuroblastoma lines. Consistent with our previously published data <xref rid="pone.0079843-Barbieri1" ref-type="bibr">[11]</xref>, Western blot analysis showed a very rapid increase in p53 levels within four hours exposure to Nutlin-3a, confirming that the p53 signaling pathway is active in our lines <bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g001">
<bold>Figure 1A and 1B</bold>
</xref>
<bold>)</bold>. Interestingly, p53 levels return to baseline at later time points, likely due to robust MDM2-mediated ubiquitination and degradation in these cell lines. We then compared the expression profiles of a <italic>MYCN</italic> amplified primary neuroblastoma line (p202) treated with Nutlin-3a or its inactive enantiomer Nutlin-3b for 3, 8, and 16 hours. As expected for a p53 wild-type tumor, we identified a large number of genes regulated by p53: 1285 genes differentially expressed between the two Nutlin treatments (class effect) and 201 genes differentially expressed between time points (time effect) <bold>(<xref ref-type="supplementary-material" rid="pone.0079843.s002">Table S1</xref> and <xref ref-type="supplementary-material" rid="pone.0079843.s003">Table S2</xref>)</bold>.</p><fig id="pone-0079843-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0079843.g001</object-id><label>Figure 1</label><caption><title>MDM2 inhibition stabilizes p53 and induces apoptosis and p53 signaling pathways in neuroblastoma cells.</title><p>(A) Consistent with our previously data <xref rid="pone.0079843-Barbieri1" ref-type="bibr">[11]</xref>, Western blotting showed an increase in p53 levels within 4 hours exposure to Nutlin-3a in p202, p218, and IMR32 cells, confirming that the p53 signaling pathway is active in our system. (B) Apoptosis induction was tested in five established neuroblastoma lines (JF, IMR32), early passage neuroblastoma tumor cultures (p202, p218, H), and four non-neuroblastoma human solid tumors including colorectal (HCT116), breast (MCF7) and osteosarcoma (SJSA-1). SJSA-1 line differs by the level of MDM2 expression, being amplified 25 fold. A p53 mutant neuroblastoma line (SJ3-12), which lacks part of the DNA binding domain, was used as control. Proliferating cells were treated with Nutlin-3a for 24 hours and TdT-positive fraction was measured by flow cytometry. (C) Pathways enriched upon Nutlin-3a treatment: p53 signaling (GSEA ID: M6370), DNA damage (GSEA ID: M8378), and chemotherapy response (bleo_human_lymph) genes. Vertical columns separate Nutlin-3a versus Nutlin-3b at 3, 8, and 16 hours, horizontal rows indicate genes.</p></caption><graphic xlink:href="pone.0079843.g001"/></fig><p>We then used Gene Set Enrichment Analysis (GSEA) to analyze genes and cellular pathways mainly affected by p53 activation. For each time point genes were ranked with respect to the average change in expression. Based on these ranked gene lists GSEA was performed <xref rid="pone.0079843-Subramanian1" ref-type="bibr">[17]</xref>. As expected, three gene sets, p53 signaling (GSEA ID: M6370), DNA repair (GSEA ID: M8378), and chemotherapy response (bleo_human_lymph) were highly up-regulated due to over expression of known p53 target genes <bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g001">
<bold>Figure 1C</bold>
</xref>
<bold>)</bold>.</p><p>By contrast, a fourth gene set was down-regulated upon p53 activation in neuroblastoma cells. This set (GSEA ID: M18562) included 57 unique genes described to be repressed both by HIF1A and hypoxia in endothelial cells (p&#x0003c;0.0001) <xref rid="pone.0079843-Manalo1" ref-type="bibr">[29]</xref>
<bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g002">
<bold>Figure 2A</bold>
</xref>
<bold>)</bold>. p53 has long been shown to play key roles in responding to DNA damage, hypoxia, and oncogenic activation. Hypoxia is also known to modulate the p53 transcriptional activity in a manner dependent and independent of HIF1A, the main transcription factor activated by hypoxia <xref rid="pone.0079843-Schmid1" ref-type="bibr">[30]</xref>. As repression of p53 functions is critical to neuroblastoma tumorigenesis, we hypothesized that these p53-repressed genes may be important in neuroblastoma biology and asked whether they could define patient outcome. We found that high expression of a subset of this gene set (25 genes) correlated with poor survival in a cohort of 56 neuroblastoma tumor samples (discovery set 5) <xref rid="pone.0079843-Wei1" ref-type="bibr">[21]</xref>
<bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g002">
<bold>Figure 2B</bold>
</xref>
<bold> and <xref ref-type="supplementary-material" rid="pone.0079843.s004">Table S3</xref>)</bold>.</p><fig id="pone-0079843-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0079843.g002</object-id><label>Figure 2</label><caption><title>Correlation of p53 repressed genes and poor prognosis.</title><p>(A) Heat map of the gene set significantly down-regulated by Nutlin-3a but not Nutlin-3b. (B) Heat map with hierarchical clustering of the gene set with respect to neuroblastoma prognosis (discovery set 5). (C) Kaplan&#x02013;Meier and log-rank analysis for progression-free (PFS) and overall (OS) survival of discovery set 2 based on 25 gene set: survival of 101 neuroblastoma patients in the 4 quartiles of the signature score. Numbers in parentheses refer to number of patients who experienced an event. (D) Multivariate logistic regression analysis: Odds Ratio and p-values are shown for disease stage (stage 4 vs. other), age (&#x0003c; or &#x0003e; 12 months), <italic>MYCN</italic> status (amplified vs. non-amplified), and the 25-gene signature score according to methods previously published <xref rid="pone.0079843-DePreter1" ref-type="bibr">[19]</xref>.</p></caption><graphic xlink:href="pone.0079843.g002"/></fig><p>We next investigated the prognostic value of this subset of 25 genes in an independent set of 101 neuroblastoma samples (discovery set 2) by calculating signature scores as previously described <xref rid="pone.0079843-DePreter1" ref-type="bibr">[19]</xref>. Increased expression of this gene set significantly correlated with poor outcome by log-rank analysis (overall survival (OS) p&#x0200a;=&#x0200a;0.00018; progression-free survival (PFS) p&#x0200a;=&#x0200a;0.00013) <bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g002">
<bold>Figure 2C</bold>
</xref>
<bold>)</bold>. In addition, multivariate analysis incorporating signature score, <italic>MYCN</italic> status, stage and age demonstrated that samples with high expression of this gene set had five times higher predicted and independent mortality than samples with low expression (odds ratio: 4.826; p&#x0200a;=&#x0200a;0.026) <bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g002">
<bold>Figure 2D</bold>
</xref>
<bold>)</bold>. The predictive power of this gene set was then independently validated in three additional clinical cohorts of high-risk patients with Kaplan-Meier and log-rank analysis (discovery set 1 <xref rid="pone.0079843-Oberthuer1" ref-type="bibr">[18]</xref> - 251 patients: OS p&#x0003c;0.00001, PFS p&#x0003c;0.00001), discovery set 3 <xref rid="pone.0079843-Wang1" ref-type="bibr">[20]</xref> - 99 patients: OS p&#x0003c;0.05, PFS p&#x0003c;0.005), and discovery set 4 - 88 patients: OS p&#x0003c;0.005 PFS, p&#x0003c;0.01) <bold>(<xref ref-type="supplementary-material" rid="pone.0079843.s001">Figure S1</xref>)</bold>.</p></sec><sec id="s3b"><title>Identification of a four-gene signature with significant prognostic value in neuroblastoma patients</title><p>We predicted that a subset of these 25 genes reflected a fundamental aspect of the p53-mediated response, and therefore we sought to define which p53 repressed genes mostly contributed to the prognostic power of this signature. Thus, a multivariate logistic regression analysis of 101 patients of the discovery set 2 (with at least 36 months follow up) was performed as described in the <xref ref-type="sec" rid="s2">Methods</xref> section. This analysis revealed a subset of four genes (CHAF1A, RRM2, MCM3, and MCM6) as independent predictor of overall survival (p&#x0003c;0.1). The correlation of survival with signature score based on the expression of these four genes was then validated in three independent data sets (discovery set 1- 251 patients: OS p&#x0003c;0.00001, PFS p&#x0003c;0.00001, discovery set 3 - 99 patients: OS p&#x0003c;0.005, PFS p&#x0003c;0.005, and discovery set 4 - 88 patients: OS p&#x0003c;0.00001, PFS p&#x0003c;0.0005) (<xref ref-type="fig" rid="pone-0079843-g003">
<bold>Figure 3A, 3B and 3C</bold>
</xref>).</p><fig id="pone-0079843-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0079843.g003</object-id><label>Figure 3</label><caption><title>The four-gene signature predict neuroblastoma outcome.</title><p>Kaplan&#x02013;Meier and log-rank analysis for progression-free (PFS) and overall (OS) survival in discovery set 1 (A), set 3 (B), and set 4 (C) based on the four-gene signature score. (D, E) Comparison of signature performance between all 25 and the 4 selected genes. Results from discovery and validation study strategy. (D) Gene predictors made in discovery set 4 and predictions made in discovery set 1. (E) Gene predictors made in validation set 4 and predictions made in discovery set 5. X axis indicates clinical factors: death event (DE), relapse event (RE), and INSS stage; Y axis indicates Area Under Curve (AUC).</p></caption><graphic xlink:href="pone.0079843.g003"/></fig><p>We also applied an alternative method based on a discovery and validation strategy to assess the power of the four genes to predict mortality, relapse, and INSS stage. A classifier able to predict these clinical factors was independently generated by the SVM (Support Vector Machine) algorithm (discovery set 4, n&#x0200a;=&#x0200a;88 patients) <xref rid="pone.0079843-Statnikov1" ref-type="bibr">[24]</xref>. The classifier was then validated in two independent patient cohorts (discovery set 1 - 251 patients and discovery set 5 &#x02013; 56 patients). ROC-curve analysis (AUC) shows that the classifier containing only the four genes performs better than the classifier containing all 25 genes in predicting mortality, relapse, and INSS stage <bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g003">
<bold>Figure 3D and 3E</bold>
</xref>
<bold>).</bold>
</p></sec><sec id="s3c"><title>Independent validation of the four-gene signature by quantitative-PCR in a large clinical cohort</title><p>Extending these findings to an additional large independent clinical cohort of neuroblastoma patients, we performed qPCR to evaluate gene expression of CHAF1A, RRM2, MCM3 and MCM6 in tumor samples from 384 patients enrolled in the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) and the Gesellschaft fuer Paediatrische Onkologie und Haematologie (GPOH) clinical trials (validation set 6) <xref rid="pone.0079843-Vermeulen1" ref-type="bibr">[22]</xref>. Both signature score and PAM classification show that the expression of these four genes as determined by qRT-PCR distinguishes patients with respect to progression-free (p&#x0003c;0&#x000b7;0001) and overall survival (p&#x0003c;0&#x000b7;0001) (<xref ref-type="fig" rid="pone-0079843-g004">
<bold>Figure 4A and 4B</bold>
</xref>). Progression-free survival at five years from the date of diagnosis was 0.793 (95% CI 0.742 &#x02013; 0.847) for the group of patients at low molecular risk compared with 0.487 (95% CI 0.366&#x02013; 0.649) for the group of patients at high molecular risk. The five year overall survival was 0.916 (95% CI: 0.878&#x02013;0.955) and 0.697 (95% CI 0.574 &#x02013;0.847) in the low and high molecular risk groups, respectively.</p><fig id="pone-0079843-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0079843.g004</object-id><label>Figure 4</label><caption><title>Independent validation of the four-gene signature in a large cohort of neuroblastoma patients (SIOPEN/GPOH).</title><p>(A) Kaplan&#x02013;Meier and log-rank analysis for progression-free (PFS) and overall (OS) survival of the SIOPEN/GPOH cohort (discovery set 6): survival of 348 neuroblastoma patients in the 4 quartiles of the signature score. (B) Validation of the signature based on the four-gene PAM classifier. (C) Classification of the SIOPEN stage 4 tumors with <italic>MYCN</italic> single copy based on the four-gene PAM classifier. (D) Multivariate logistic regression analysis: Odds Ratio and p-values are shown for disease stage (stage 4 vs. other), age (&#x0003c;&#x0003e; 1y), <italic>MYCN</italic> status, and the four-gene signature score.</p></caption><graphic xlink:href="pone.0079843.g004"/></fig><p>Currently, the strongest predictive risk factors used for neuroblastoma risk stratification are age, stage, tumor histology, and <italic>MYCN</italic> gene amplification status. Multivariate logistic regression analysis revealed that high expression of the four genes predicts poor survival independently of these clinical features (odds ratio: 2.4; p&#x0003c;0.01) <bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g004">
<bold>Figure 4D</bold>
</xref>
<bold>)</bold>. To validate that the four-gene signature was independent of the major risk factor, <italic>MYCN</italic> status, we analyzed only the <italic>MYCN</italic> single copy stage 4 tumors. Indeed, the signature can efficiently predict survival in this group of patients lacking <italic>MYCN</italic> gene amplification (log-rank analysis, p&#x0003c; 0.05) <bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g004">
<bold>Figure 4C</bold>
</xref>
<bold>)</bold>.</p></sec><sec id="s3d"><title>The four-gene signature is repressed by p53 in neuroblastoma cells</title><p>To test that the expression of these four genes is indeed regulated by p53, gene expression of RRM2, CHAF1A, MCM3, and MCM6 was assessed in multiple p53 wild-type neuroblastoma lines treated with Nutlin-3a. Real-time PCR demonstrated robust and rapid repression of each of these genes upon treatment (p&#x0003c;0.005). However, this effect was totally abrogated in neuroblastoma p53 mutant (LAN1) cell line which lacks a DNA binding domain. In addition, we used ShRNA-mediated knockdown of p53 in several cell lines and confirmed up-regulation of all four target genes <bold>(</bold>
<xref ref-type="fig" rid="pone-0079843-g005">
<bold>Figure 5A, 5B and 5C</bold>
</xref>
<bold>).</bold> Furthermore, analysis of two publically available independent ChIP-seq data sets <xref rid="pone.0079843-Koeppel1" ref-type="bibr">[31]</xref>, <xref rid="pone.0079843-Botcheva1" ref-type="bibr">[32]</xref> confirms clear p53 binding to p53 response elements in the promoters of these four genes in response to p53 activation (data not shown). Taken together, these data suggest that these genes are direct p53 transcriptional targets.</p><fig id="pone-0079843-g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0079843.g005</object-id><label>Figure 5</label><caption><title>The four-gene signature is regulated by p53 activity.</title><p>Activation of p53 represses the four-gene signature. (A, B) Quantitative PCR demonstrates marked decrease of mRNA levels of the four genes after Nutlin-3a treatment (10 uM for 8 hours) in multiple p53 wild-type neuroblastoma lines (shown here LAN5 and IMR32). However, this effect is completely abrogated after p53 silencing or when the effect of Nutlin-3a is tested in a p53 mutant neuroblastoma cell line (LAN1) (C). Each error bar represents two biological replicates.</p></caption><graphic xlink:href="pone.0079843.g005"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>As noted above, p53 is rarely mutated in neuroblastoma, suggesting that repression of downstream effector genes is critical for tumorigenesis. p53 is a potent transcription factor that positively and negatively modulates a large number of genes involved in apoptosis, metabolism, epigenetics, and cell cycle regulation <xref rid="pone.0079843-Lozano1" ref-type="bibr">[33]</xref>, <xref rid="pone.0079843-Lane1" ref-type="bibr">[34]</xref>. We used Nutlin-3a, a direct inhibitor of the p53 E-3 ligase MDM2, to investigate how the p53 drug response signature is regulated in high-risk neuroblastoma. Starting from the analysis of a gene set repressed by p53 activity and highly expressed in high-risk neuroblastoma, we identified a novel four-gene signature of prognostic relevance. In our retrospective analysis of three large independent cohorts of neuroblastoma patients (540 patients total) and 348 patients enrolled in the SIOPEN/GPOH, this four-gene signature classifies patients with respect to survival independently of current clinical classification scheme based on age, stage, <italic>MYCN</italic> expression and histological features (INRG Staging System <xref rid="pone.0079843-Cohn1" ref-type="bibr">[3]</xref>). Notably, our four-gene signature shows predictive value in neuroblastoma patients with stage 4 disease and without <italic>MYCN</italic> amplification. As over 50% of these patients will relapse and succumb to neuroblastoma despite current risk stratifications, there is clearly a need for additional identification of higher risk subgroups that could be given alternative or additional therapies.</p><p>The four genes constituting the signature are involved in DNA replication and chromatin remodeling. In addition, along with other genes involved in cell growth, they have been described as repressed by HIF1A and hypoxia in endothelial cells <xref rid="pone.0079843-Manalo1" ref-type="bibr">[29]</xref>. It is well known that tumor microenvironment is intimately connected with neuroblastoma biology <xref rid="pone.0079843-Harris1" ref-type="bibr">[35]</xref>, <xref rid="pone.0079843-HolmquistMengelbier1" ref-type="bibr">[36]</xref>, <xref rid="pone.0079843-Qing1" ref-type="bibr">[37]</xref>. While the influence of HIF1A on the expression of these four genes in neuroblastoma remains to be defined, we demonstrated that their expression strongly correlates with poor outcome.</p><p>These four genes are likely to have roles in determining neuroblastoma behavior. RRM2, MCM3 and MCM6 genes have all been described as cell cycle regulatory genes repressed by p53 in other models as well <xref rid="pone.0079843-Spurgers1" ref-type="bibr">[13]</xref>, <xref rid="pone.0079843-Xue1" ref-type="bibr">[38]</xref>. Ribonucleotide Reductase M2 subunit (RRM2), which is expressed when DNA replication occurs, is overexpressed in a number of solid tumors and is an established anti-cancer target <xref rid="pone.0079843-Cerqueira1" ref-type="bibr">[15]</xref>. Additional evidence suggests that Ribonucleotide Reductase (RR) acts as a positive determinant for tumor cell proliferation and metastasis as well as the development of chemoresistance <xref rid="pone.0079843-Bhutia1" ref-type="bibr">[39]</xref>. p53 and RRM2 also directly interact to regulate DNA damage responses <xref rid="pone.0079843-Xue1" ref-type="bibr">[38]</xref>. A recent phase I clinical trial involving the administration of RRM2 siRNA via nanoparticle to patients with solid cancers showed promising results <xref rid="pone.0079843-Davis1" ref-type="bibr">[40]</xref>. In addition, several inhibitors (like triapine and GTI-2040) have been studied as potential inhibitors of RRM2 activity and have been evaluated in phase I clinical trials <xref rid="pone.0079843-Shao1" ref-type="bibr">[41]</xref>. A recent study suggests that RRM2 contributes to the stabilization of Bcl-2, a marker of chemoresistance <xref rid="pone.0079843-Rahman1" ref-type="bibr">[42]</xref>. BCL2 levels are high in the majority of neuroblastoma tumors. These observations suggest that suppression of Bcl-2 by targeting RRM2 may be an effective strategy for restoring chemo-sensitivity in neuroblastoma.</p><p>Growing data support the importance of perturbations of the DNA replication machinery in driving cancer. The minichromosome maintenance (MCM) gene family is essential for DNA replication and is frequently upregulated in various cancers. Furthermore, increased expression of MCM genes has been shown to correlate with poorer patient survival rates in other tumor types <xref rid="pone.0079843-Ramnath1" ref-type="bibr">[43]</xref>, <xref rid="pone.0079843-Meng1" ref-type="bibr">[44]</xref>, <xref rid="pone.0079843-Majid1" ref-type="bibr">[45]</xref>. Notably, all the MCM genes, including MCM7, are direct transcriptional targets of <italic>MYCN</italic> and E2F <xref rid="pone.0079843-Koppen1" ref-type="bibr">[16]</xref>, <xref rid="pone.0079843-Shohet1" ref-type="bibr">[46]</xref>. In addition, deregulation of G1-S checkpoint and E2F target genes correlates with poor outcome in neuroblastoma <xref rid="pone.0079843-Molenaar2" ref-type="bibr">[47]</xref>, further supporting a potential oncogenic role of MCM genes in neuroblastoma.</p><p>The histone chaperone molecule, CHAF1A (CAF p150), is a primary component of the chromatin assembly factor 1 (CAF-1) which is vital for DNA assembly during S-phase <xref rid="pone.0079843-Hoek1" ref-type="bibr">[14]</xref>, <xref rid="pone.0079843-Reese1" ref-type="bibr">[48]</xref>. CHAF1A inactivates cell proliferation, regulates DNA repair, and controls epigenetic marking in embryonic stem cells <xref rid="pone.0079843-Houlard1" ref-type="bibr">[49]</xref>. CHAF1A is also a known epigenetic modifier. By participating in a complex with MBD1 and SETDB1, CHAF1A promotes H3K9 trimethylation and heterochromatin formation <xref rid="pone.0079843-Reese1" ref-type="bibr">[48]</xref>, <xref rid="pone.0079843-Poleshko1" ref-type="bibr">[50]</xref>. Importantly, CHAF1A overexpression has been linked to tumor progression, genomic instability, and cancer susceptibility in other tumor types including glioma <xref rid="pone.0079843-Glinsky1" ref-type="bibr">[51]</xref>, <xref rid="pone.0079843-Jiao1" ref-type="bibr">[52]</xref>, <xref rid="pone.0079843-Bethke1" ref-type="bibr">[53]</xref>.</p><p>The tumor suppressor p53 is very rarely mutated in primary neuroblastoma at diagnosis and its downstream effectors are functionally intact <xref rid="pone.0079843-CarrWilkinson1" ref-type="bibr">[8]</xref>, <xref rid="pone.0079843-VanMaerken2" ref-type="bibr">[54]</xref>. However, multiple hits seem to cooperate to impair p53 functions in neuroblastoma, including deregulation of the ARF/MDM2 pathway <xref rid="pone.0079843-Kim1" ref-type="bibr">[55]</xref>, expression of microRNAs targeting p53 pathways <xref rid="pone.0079843-Swarbrick1" ref-type="bibr">[56]</xref>, and repression of p53-mediated autophagy <xref rid="pone.0079843-Maiuri1" ref-type="bibr">[57]</xref>. We demonstrate here that transcriptional profiles of high-risk neuroblastoma show <italic>over- expression</italic> of genes that are <italic>repressed</italic> by p53, and furthermore, a subset of these genes has strong prognostic value, suggesting they are involved in overcoming chemotherapy-induced p53 activity. The therapeutic approach of &#x02018;reactivating p53&#x02019; (e.g. by MDM2 antagonists, or delivery of wild type p53) for neuroblastoma, which develops in the context of <italic>MYCN</italic>-mediated p53 repression is an active area of investigation with several early phase clinical trials underway <xref rid="pone.0079843-Carol1" ref-type="bibr">[58]</xref>, <xref rid="pone.0079843-Ding1" ref-type="bibr">[59]</xref>. Our data further support these approaches and suggest additional targets for incorporation into future translational studies.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0079843.s001"><label>Figure S1</label><caption><p>
<bold>Kaplan-Meier and log-rank analysis for progression free and overall survival of three independent cohorts of NB patients stratified according the expression of the 25 genes.</bold> Survival of 251 patients of discovery set 1 (A), 99 patients of discovery set 3 (B), and 88 patients of discovery set 4 (C) in the 4 quartiles of the signature score. Represented is the number of patients at low and high-risk as predicted by the 25-gene signature. Numbers in parentheses refer to number of patients who experienced an event.</p><p>(TIFF)</p></caption><media xlink:href="pone.0079843.s001.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0079843.s002"><label>Table S1</label><caption><p>
<bold>Selected genes modulated by Nutlin-3a treatment.</bold> Genes differentially expressed between Nutlin-3a and Nutlin-3b treatment (class effect &#x02013; <xref ref-type="supplementary-material" rid="pone.0079843.s002">Table S1</xref>) and between time points (time effect &#x02013; <xref ref-type="supplementary-material" rid="pone.0079843.s003">Table S2</xref>) are listed.</p><p>(XLSX)</p></caption><media xlink:href="pone.0079843.s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0079843.s003"><label>Table S2</label><caption><p>
<bold>Selected genes modulated by Nutlin-3a treatment.</bold> Genes differentially expressed between Nutlin-3a and Nutlin-3b treatment (class effect &#x02013; <xref ref-type="supplementary-material" rid="pone.0079843.s002">Table S1</xref>) and between time points (time effect &#x02013; <xref ref-type="supplementary-material" rid="pone.0079843.s003">Table S2</xref>) are listed.</p><p>(XLSX)</p></caption><media xlink:href="pone.0079843.s003.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0079843.s004"><label>Table S3</label><caption><p>
<bold>Correlation of the 25 genes with survival in discovery set 5.</bold> The list of the 25 genes repressed by p53 and the correlation of their expression with stage of disease in 56 neuroblastoma patients are shown.</p><p>(XLS)</p></caption><media xlink:href="pone.0079843.s004.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank John M. Maris, Andr&#x000e9; Oberthuer, and the SIOPEN for the data sets, Steve Lefever and Els De Smet for technical help with qPCR analysis, and Agarwal Saurabh the CHIP-seq validation analysis.</p></ack><ref-list><title>References</title><ref id="pone.0079843-Maris1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Maris</surname><given-names>JM</given-names></name> (<year>2010</year>) <article-title>Recent advances in neuroblastoma</article-title>. <source>N Engl J Med</source>
<volume>362</volume>: <fpage>2202</fpage>&#x02013;<lpage>2211</lpage>.<pub-id pub-id-type="pmid">20558371</pub-id></mixed-citation></ref><ref id="pone.0079843-Speleman1"><label>2</label><mixed-citation publication-type="other">Speleman F, De Preter K, Vandesompele J (2011) Neuroblastoma genetics and phenotype: A tale of heterogeneity. Semin Cancer Biol.</mixed-citation></ref><ref id="pone.0079843-Cohn1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Cohn</surname><given-names>SL</given-names></name>, <name><surname>Pearson</surname><given-names>AD</given-names></name>, <name><surname>London</surname><given-names>WB</given-names></name>, <name><surname>Monclair</surname><given-names>T</given-names></name>, <name><surname>Ambros</surname><given-names>PF</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report</article-title>. <source>J Clin Oncol</source>
<volume>27</volume>: <fpage>289</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">19047291</pub-id></mixed-citation></ref><ref id="pone.0079843-JanoueixLerosey1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Janoueix-Lerosey</surname><given-names>I</given-names></name>, <name><surname>Lequin</surname><given-names>D</given-names></name>, <name><surname>Brugieres</surname><given-names>L</given-names></name>, <name><surname>Ribeiro</surname><given-names>A</given-names></name>, <name><surname>de Pontual</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</article-title>. <source>Nature</source>
<volume>455</volume>: <fpage>967</fpage>&#x02013;<lpage>970</lpage>.<pub-id pub-id-type="pmid">18923523</pub-id></mixed-citation></ref><ref id="pone.0079843-Molenaar1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Molenaar</surname><given-names>JJ</given-names></name>, <name><surname>Koster</surname><given-names>J</given-names></name>, <name><surname>Zwijnenburg</surname><given-names>DA</given-names></name>, <name><surname>van Sluis</surname><given-names>P</given-names></name>, <name><surname>Valentijn</surname><given-names>LJ</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes</article-title>. <source>Nature</source>
<volume>483</volume>: <fpage>589</fpage>&#x02013;<lpage>593</lpage>.<pub-id pub-id-type="pmid">22367537</pub-id></mixed-citation></ref><ref id="pone.0079843-Chen1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Takita</surname><given-names>J</given-names></name>, <name><surname>Choi</surname><given-names>YL</given-names></name>, <name><surname>Kato</surname><given-names>M</given-names></name>, <name><surname>Ohira</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Oncogenic mutations of ALK kinase in neuroblastoma</article-title>. <source>Nature</source>
<volume>455</volume>: <fpage>971</fpage>&#x02013;<lpage>974</lpage>.<pub-id pub-id-type="pmid">18923524</pub-id></mixed-citation></ref><ref id="pone.0079843-Carr1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Carr</surname><given-names>J</given-names></name>, <name><surname>Bell</surname><given-names>E</given-names></name>, <name><surname>Pearson</surname><given-names>AD</given-names></name>, <name><surname>Kees</surname><given-names>UR</given-names></name>, <name><surname>Beris</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse</article-title>. <source>Cancer Res</source>
<volume>66</volume>: <fpage>2138</fpage>&#x02013;<lpage>2145</lpage>.<pub-id pub-id-type="pmid">16489014</pub-id></mixed-citation></ref><ref id="pone.0079843-CarrWilkinson1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Carr-Wilkinson</surname><given-names>J</given-names></name>, <name><surname>O'Toole</surname><given-names>K</given-names></name>, <name><surname>Wood</surname><given-names>KM</given-names></name>, <name><surname>Challen</surname><given-names>CC</given-names></name>, <name><surname>Baker</surname><given-names>AG</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma</article-title>. <source>Clin Cancer Res</source>
<volume>16</volume>: <fpage>1108</fpage>&#x02013;<lpage>1118</lpage>.<pub-id pub-id-type="pmid">20145180</pub-id></mixed-citation></ref><ref id="pone.0079843-Chen2"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Lin</surname><given-names>Y</given-names></name>, <name><surname>Barbieri</surname><given-names>E</given-names></name>, <name><surname>Burlingame</surname><given-names>S</given-names></name>, <name><surname>Hicks</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo</article-title>. <source>Neoplasia</source>
<volume>11</volume>: <fpage>753</fpage>&#x02013;<lpage>762</lpage>.<pub-id pub-id-type="pmid">19649205</pub-id></mixed-citation></ref><ref id="pone.0079843-Vassilev1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Vassilev</surname><given-names>LT</given-names></name>, <name><surname>Vu</surname><given-names>BT</given-names></name>, <name><surname>Graves</surname><given-names>B</given-names></name>, <name><surname>Carvajal</surname><given-names>D</given-names></name>, <name><surname>Podlaski</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>In vivo activation of the p53 pathway by small-molecule antagonists of MDM2</article-title>. <source>Science</source>
<volume>303</volume>: <fpage>844</fpage>&#x02013;<lpage>848</lpage>.<pub-id pub-id-type="pmid">14704432</pub-id></mixed-citation></ref><ref id="pone.0079843-Barbieri1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Barbieri</surname><given-names>E</given-names></name>, <name><surname>Mehta</surname><given-names>P</given-names></name>, <name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Slack</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death</article-title>. <source>Mol Cancer Ther</source>
<volume>5</volume>: <fpage>2358</fpage>&#x02013;<lpage>2365</lpage>.<pub-id pub-id-type="pmid">16985070</pub-id></mixed-citation></ref><ref id="pone.0079843-VanMaerken1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Van Maerken</surname><given-names>T</given-names></name>, <name><surname>Ferdinande</surname><given-names>L</given-names></name>, <name><surname>Taildeman</surname><given-names>J</given-names></name>, <name><surname>Lambertz</surname><given-names>I</given-names></name>, <name><surname>Yigit</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53</article-title>. <source>J Natl Cancer Inst</source>
<volume>101</volume>: <fpage>1562</fpage>&#x02013;<lpage>1574</lpage>.<pub-id pub-id-type="pmid">19903807</pub-id></mixed-citation></ref><ref id="pone.0079843-Spurgers1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Spurgers</surname><given-names>KB</given-names></name>, <name><surname>Gold</surname><given-names>DL</given-names></name>, <name><surname>Coombes</surname><given-names>KR</given-names></name>, <name><surname>Bohnenstiehl</surname><given-names>NL</given-names></name>, <name><surname>Mullins</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression</article-title>. <source>J Biol Chem</source>
<volume>281</volume>: <fpage>25134</fpage>&#x02013;<lpage>25142</lpage>.<pub-id pub-id-type="pmid">16798743</pub-id></mixed-citation></ref><ref id="pone.0079843-Hoek1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Hoek</surname><given-names>M</given-names></name>, <name><surname>Stillman</surname><given-names>B</given-names></name> (<year>2003</year>) <article-title>Chromatin assembly factor 1 is essential and couples chromatin assembly to DNA replication in vivo</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>100</volume>: <fpage>12183</fpage>&#x02013;<lpage>12188</lpage>.<pub-id pub-id-type="pmid">14519857</pub-id></mixed-citation></ref><ref id="pone.0079843-Cerqueira1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Cerqueira</surname><given-names>NM</given-names></name>, <name><surname>Pereira</surname><given-names>S</given-names></name>, <name><surname>Fernandes</surname><given-names>PA</given-names></name>, <name><surname>Ramos</surname><given-names>MJ</given-names></name> (<year>2005</year>) <article-title>Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy</article-title>. <source>Curr Med Chem</source>
<volume>12</volume>: <fpage>1283</fpage>&#x02013;<lpage>1294</lpage>.<pub-id pub-id-type="pmid">15974997</pub-id></mixed-citation></ref><ref id="pone.0079843-Koppen1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Koppen</surname><given-names>A</given-names></name>, <name><surname>Ait-Aissa</surname><given-names>R</given-names></name>, <name><surname>Koster</surname><given-names>J</given-names></name>, <name><surname>van Sluis</surname><given-names>PG</given-names></name>, <name><surname>Ora</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma</article-title>. <source>Eur J Cancer</source>
<volume>43</volume>: <fpage>2413</fpage>&#x02013;<lpage>2422</lpage>.<pub-id pub-id-type="pmid">17826980</pub-id></mixed-citation></ref><ref id="pone.0079843-Subramanian1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Subramanian</surname><given-names>A</given-names></name>, <name><surname>Tamayo</surname><given-names>P</given-names></name>, <name><surname>Mootha</surname><given-names>VK</given-names></name>, <name><surname>Mukherjee</surname><given-names>S</given-names></name>, <name><surname>Ebert</surname><given-names>BL</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>102</volume>: <fpage>15545</fpage>&#x02013;<lpage>15550</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation></ref><ref id="pone.0079843-Oberthuer1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Oberthuer</surname><given-names>A</given-names></name>, <name><surname>Berthold</surname><given-names>F</given-names></name>, <name><surname>Warnat</surname><given-names>P</given-names></name>, <name><surname>Hero</surname><given-names>B</given-names></name>, <name><surname>Kahlert</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification</article-title>. <source>J Clin Oncol</source>
<volume>24</volume>: <fpage>5070</fpage>&#x02013;<lpage>5078</lpage>.<pub-id pub-id-type="pmid">17075126</pub-id></mixed-citation></ref><ref id="pone.0079843-DePreter1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>De Preter</surname><given-names>K</given-names></name>, <name><surname>Vermeulen</surname><given-names>J</given-names></name>, <name><surname>Brors</surname><given-names>B</given-names></name>, <name><surname>Delattre</surname><given-names>O</given-names></name>, <name><surname>Eggert</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature</article-title>. <source>Clin Cancer Res</source>
<volume>16</volume>: <fpage>1532</fpage>&#x02013;<lpage>1541</lpage>.<pub-id pub-id-type="pmid">20179214</pub-id></mixed-citation></ref><ref id="pone.0079843-Wang1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Diskin</surname><given-names>S</given-names></name>, <name><surname>Rappaport</surname><given-names>E</given-names></name>, <name><surname>Attiyeh</surname><given-names>E</given-names></name>, <name><surname>Mosse</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number</article-title>. <source>Cancer Res</source>
<volume>66</volume>: <fpage>6050</fpage>&#x02013;<lpage>6062</lpage>.<pub-id pub-id-type="pmid">16778177</pub-id></mixed-citation></ref><ref id="pone.0079843-Wei1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Wei</surname><given-names>JS</given-names></name>, <name><surname>Greer</surname><given-names>BT</given-names></name>, <name><surname>Westermann</surname><given-names>F</given-names></name>, <name><surname>Steinberg</surname><given-names>SM</given-names></name>, <name><surname>Son</surname><given-names>CG</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma</article-title>. <source>Cancer Res</source>
<volume>64</volume>: <fpage>6883</fpage>&#x02013;<lpage>6891</lpage>.<pub-id pub-id-type="pmid">15466177</pub-id></mixed-citation></ref><ref id="pone.0079843-Vermeulen1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Vermeulen</surname><given-names>J</given-names></name>, <name><surname>De Preter</surname><given-names>K</given-names></name>, <name><surname>Laureys</surname><given-names>G</given-names></name>, <name><surname>Speleman</surname><given-names>F</given-names></name>, <name><surname>Vandesompele</surname><given-names>J</given-names></name> (<year>2009</year>) <article-title>59-gene prognostic signature sub-stratifies high-risk neuroblastoma patients</article-title>. <source>Lancet Oncol</source>
<volume>10</volume>: <fpage>1030</fpage>.<pub-id pub-id-type="pmid">19880060</pub-id></mixed-citation></ref><ref id="pone.0079843-Fredlund1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Fredlund</surname><given-names>E</given-names></name>, <name><surname>Ringner</surname><given-names>M</given-names></name>, <name><surname>Maris</surname><given-names>JM</given-names></name>, <name><surname>Pahlman</surname><given-names>S</given-names></name> (<year>2008</year>) <article-title>High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>105</volume>: <fpage>14094</fpage>&#x02013;<lpage>14099</lpage>.<pub-id pub-id-type="pmid">18780787</pub-id></mixed-citation></ref><ref id="pone.0079843-Statnikov1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Statnikov</surname><given-names>A</given-names></name>, <name><surname>Tsamardinos</surname><given-names>I</given-names></name>, <name><surname>Dosbayev</surname><given-names>Y</given-names></name>, <name><surname>Aliferis</surname><given-names>CF</given-names></name> (<year>2005</year>) <article-title>GEMS: a system for automated cancer diagnosis and biomarker discovery from microarray gene expression data</article-title>. <source>Int J Med Inform</source>
<volume>74</volume>: <fpage>491</fpage>&#x02013;<lpage>503</lpage>.<pub-id pub-id-type="pmid">15967710</pub-id></mixed-citation></ref><ref id="pone.0079843-Lefever1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Lefever</surname><given-names>S</given-names></name>, <name><surname>Vandesompele</surname><given-names>J</given-names></name>, <name><surname>Speleman</surname><given-names>F</given-names></name>, <name><surname>Pattyn</surname><given-names>F</given-names></name> (<year>2009</year>) <article-title>RTPrimerDB: the portal for real-time PCR primers and probes</article-title>. <source>Nucleic Acids Res</source>
<volume>37</volume>: <fpage>D942</fpage>&#x02013;<lpage>945</lpage>.<pub-id pub-id-type="pmid">18948285</pub-id></mixed-citation></ref><ref id="pone.0079843-Hellemans1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Hellemans</surname><given-names>J</given-names></name>, <name><surname>Mortier</surname><given-names>G</given-names></name>, <name><surname>De Paepe</surname><given-names>A</given-names></name>, <name><surname>Speleman</surname><given-names>F</given-names></name>, <name><surname>Vandesompele</surname><given-names>J</given-names></name> (<year>2007</year>) <article-title>qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data</article-title>. <source>Genome Biol</source>
<volume>8</volume>: <fpage>R19</fpage>.<pub-id pub-id-type="pmid">17291332</pub-id></mixed-citation></ref><ref id="pone.0079843-Lefever2"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Lefever</surname><given-names>S</given-names></name>, <name><surname>Hellemans</surname><given-names>J</given-names></name>, <name><surname>Pattyn</surname><given-names>F</given-names></name>, <name><surname>Przybylski</surname><given-names>DR</given-names></name>, <name><surname>Taylor</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>RDML: structured language and reporting guidelines for real-time quantitative PCR data</article-title>. <source>Nucleic Acids Res</source>
<volume>37</volume>: <fpage>2065</fpage>&#x02013;<lpage>2069</lpage>.<pub-id pub-id-type="pmid">19223324</pub-id></mixed-citation></ref><ref id="pone.0079843-Budanov1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Budanov</surname><given-names>AV</given-names></name>, <name><surname>Sablina</surname><given-names>AA</given-names></name>, <name><surname>Feinstein</surname><given-names>E</given-names></name>, <name><surname>Koonin</surname><given-names>EV</given-names></name>, <name><surname>Chumakov</surname><given-names>PM</given-names></name> (<year>2004</year>) <article-title>Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD</article-title>. <source>Science</source>
<volume>304</volume>: <fpage>596</fpage>&#x02013;<lpage>600</lpage>.<pub-id pub-id-type="pmid">15105503</pub-id></mixed-citation></ref><ref id="pone.0079843-Manalo1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Manalo</surname><given-names>DJ</given-names></name>, <name><surname>Rowan</surname><given-names>A</given-names></name>, <name><surname>Lavoie</surname><given-names>T</given-names></name>, <name><surname>Natarajan</surname><given-names>L</given-names></name>, <name><surname>Kelly</surname><given-names>BD</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1</article-title>. <source>Blood</source>
<volume>105</volume>: <fpage>659</fpage>&#x02013;<lpage>669</lpage>.<pub-id pub-id-type="pmid">15374877</pub-id></mixed-citation></ref><ref id="pone.0079843-Schmid1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Schmid</surname><given-names>T</given-names></name>, <name><surname>Zhou</surname><given-names>J</given-names></name>, <name><surname>Kohl</surname><given-names>R</given-names></name>, <name><surname>Brune</surname><given-names>B</given-names></name> (<year>2004</year>) <article-title>p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1)</article-title>. <source>Biochem J</source>
<volume>380</volume>: <fpage>289</fpage>&#x02013;<lpage>295</lpage>.<pub-id pub-id-type="pmid">14992692</pub-id></mixed-citation></ref><ref id="pone.0079843-Koeppel1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Koeppel</surname><given-names>M</given-names></name>, <name><surname>van Heeringen</surname><given-names>SJ</given-names></name>, <name><surname>Kramer</surname><given-names>D</given-names></name>, <name><surname>Smeenk</surname><given-names>L</given-names></name>, <name><surname>Janssen-Megens</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Crosstalk between c-Jun and TAp73alpha/beta contributes to the apoptosis-survival balance</article-title>. <source>Nucleic Acids Res</source>
<volume>39</volume>: <fpage>6069</fpage>&#x02013;<lpage>6085</lpage>.<pub-id pub-id-type="pmid">21459846</pub-id></mixed-citation></ref><ref id="pone.0079843-Botcheva1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Botcheva</surname><given-names>K</given-names></name>, <name><surname>McCorkle</surname><given-names>SR</given-names></name>, <name><surname>McCombie</surname><given-names>WR</given-names></name>, <name><surname>Dunn</surname><given-names>JJ</given-names></name>, <name><surname>Anderson</surname><given-names>CW</given-names></name> (<year>2011</year>) <article-title>Distinct p53 genomic binding patterns in normal and cancer-derived human cells</article-title>. <source>Cell Cycle</source>
<volume>10</volume>: <fpage>4237</fpage>&#x02013;<lpage>4249</lpage>.<pub-id pub-id-type="pmid">22127205</pub-id></mixed-citation></ref><ref id="pone.0079843-Lozano1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Lozano</surname><given-names>G</given-names></name> (<year>2010</year>) <article-title>Mouse models of p53 functions</article-title>. <source>Cold Spring Harb Perspect Biol</source>
<volume>2</volume>: <fpage>a001115</fpage>.<pub-id pub-id-type="pmid">20452944</pub-id></mixed-citation></ref><ref id="pone.0079843-Lane1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Lane</surname><given-names>D</given-names></name>, <name><surname>Levine</surname><given-names>A</given-names></name> (<year>2010</year>) <article-title>p53 Research: the past thirty years and the next thirty years</article-title>. <source>Cold Spring Harb Perspect Biol</source>
<volume>2</volume>: <fpage>a000893</fpage>.<pub-id pub-id-type="pmid">20463001</pub-id></mixed-citation></ref><ref id="pone.0079843-Harris1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Harris</surname><given-names>AL</given-names></name> (<year>2002</year>) <article-title>Hypoxia&#x02014;a key regulatory factor in tumour growth</article-title>. <source>Nat Rev Cancer</source>
<volume>2</volume>: <fpage>38</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">11902584</pub-id></mixed-citation></ref><ref id="pone.0079843-HolmquistMengelbier1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Holmquist-Mengelbier</surname><given-names>L</given-names></name>, <name><surname>Fredlund</surname><given-names>E</given-names></name>, <name><surname>Lofstedt</surname><given-names>T</given-names></name>, <name><surname>Noguera</surname><given-names>R</given-names></name>, <name><surname>Navarro</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype</article-title>. <source>Cancer Cell</source>
<volume>10</volume>: <fpage>413</fpage>&#x02013;<lpage>423</lpage>.<pub-id pub-id-type="pmid">17097563</pub-id></mixed-citation></ref><ref id="pone.0079843-Qing1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Qing</surname><given-names>G</given-names></name>, <name><surname>Skuli</surname><given-names>N</given-names></name>, <name><surname>Mayes</surname><given-names>PA</given-names></name>, <name><surname>Pawel</surname><given-names>B</given-names></name>, <name><surname>Martinez</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha</article-title>. <source>Cancer Res</source>
<volume>70</volume>: <fpage>10351</fpage>&#x02013;<lpage>10361</lpage>.<pub-id pub-id-type="pmid">20961996</pub-id></mixed-citation></ref><ref id="pone.0079843-Xue1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Xue</surname><given-names>L</given-names></name>, <name><surname>Zhou</surname><given-names>B</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Qiu</surname><given-names>W</given-names></name>, <name><surname>Jin</surname><given-names>Z</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits</article-title>. <source>Cancer Res</source>
<volume>63</volume>: <fpage>980</fpage>&#x02013;<lpage>986</lpage>.<pub-id pub-id-type="pmid">12615712</pub-id></mixed-citation></ref><ref id="pone.0079843-Bhutia1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Bhutia</surname><given-names>YD</given-names></name>, <name><surname>Hung</surname><given-names>SW</given-names></name>, <name><surname>Krentz</surname><given-names>M</given-names></name>, <name><surname>Patel</surname><given-names>D</given-names></name>, <name><surname>Lovin</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein</article-title>. <source>PLoS One</source>
<volume>8</volume>: <fpage>e53436</fpage>.<pub-id pub-id-type="pmid">23335963</pub-id></mixed-citation></ref><ref id="pone.0079843-Davis1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Davis</surname><given-names>ME</given-names></name>, <name><surname>Zuckerman</surname><given-names>JE</given-names></name>, <name><surname>Choi</surname><given-names>CH</given-names></name>, <name><surname>Seligson</surname><given-names>D</given-names></name>, <name><surname>Tolcher</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles</article-title>. <source>Nature</source>
<volume>464</volume>: <fpage>1067</fpage>&#x02013;<lpage>1070</lpage>.<pub-id pub-id-type="pmid">20305636</pub-id></mixed-citation></ref><ref id="pone.0079843-Shao1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Shao</surname><given-names>J</given-names></name>, <name><surname>Zhou</surname><given-names>B</given-names></name>, <name><surname>Chu</surname><given-names>B</given-names></name>, <name><surname>Yen</surname><given-names>Y</given-names></name> (<year>2006</year>) <article-title>Ribonucleotide reductase inhibitors and future drug design</article-title>. <source>Curr Cancer Drug Targets</source>
<volume>6</volume>: <fpage>409</fpage>&#x02013;<lpage>431</lpage>.<pub-id pub-id-type="pmid">16918309</pub-id></mixed-citation></ref><ref id="pone.0079843-Rahman1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Rahman</surname><given-names>MA</given-names></name>, <name><surname>Amin</surname><given-names>AR</given-names></name>, <name><surname>Wang</surname><given-names>D</given-names></name>, <name><surname>Koenig</surname><given-names>L</given-names></name>, <name><surname>Nannapaneni</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>RRM2 Regulates Bcl-2 in Head and Neck and Lung Cancers: A Potential Target for Cancer Therapy</article-title>. <source>Clin Cancer Res</source>
<volume>19</volume>: <fpage>3416</fpage>&#x02013;<lpage>3428</lpage>.<pub-id pub-id-type="pmid">23719266</pub-id></mixed-citation></ref><ref id="pone.0079843-Ramnath1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Ramnath</surname><given-names>N</given-names></name>, <name><surname>Hernandez</surname><given-names>FJ</given-names></name>, <name><surname>Tan</surname><given-names>DF</given-names></name>, <name><surname>Huberman</surname><given-names>JA</given-names></name>, <name><surname>Natarajan</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source>
<volume>19</volume>: <fpage>4259</fpage>&#x02013;<lpage>4266</lpage>.<pub-id pub-id-type="pmid">11709570</pub-id></mixed-citation></ref><ref id="pone.0079843-Meng1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Meng</surname><given-names>MV</given-names></name>, <name><surname>Grossfeld</surname><given-names>GD</given-names></name>, <name><surname>Williams</surname><given-names>GH</given-names></name>, <name><surname>Dilworth</surname><given-names>S</given-names></name>, <name><surname>Stoeber</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer</article-title>. <source>Clin Cancer Res</source>
<volume>7</volume>: <fpage>2712</fpage>&#x02013;<lpage>2718</lpage>.<pub-id pub-id-type="pmid">11555583</pub-id></mixed-citation></ref><ref id="pone.0079843-Majid1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Majid</surname><given-names>S</given-names></name>, <name><surname>Dar</surname><given-names>AA</given-names></name>, <name><surname>Saini</surname><given-names>S</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Shahryari</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer</article-title>. <source>Cancer Res</source>
<volume>70</volume>: <fpage>2809</fpage>&#x02013;<lpage>2818</lpage>.<pub-id pub-id-type="pmid">20332239</pub-id></mixed-citation></ref><ref id="pone.0079843-Shohet1"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Shohet</surname><given-names>JM</given-names></name>, <name><surname>Hicks</surname><given-names>MJ</given-names></name>, <name><surname>Plon</surname><given-names>SE</given-names></name>, <name><surname>Burlingame</surname><given-names>SM</given-names></name>, <name><surname>Stuart</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma</article-title>. <source>Cancer Res</source>
<volume>62</volume>: <fpage>1123</fpage>&#x02013;<lpage>1128</lpage>.<pub-id pub-id-type="pmid">11861392</pub-id></mixed-citation></ref><ref id="pone.0079843-Molenaar2"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Molenaar</surname><given-names>JJ</given-names></name>, <name><surname>Koster</surname><given-names>J</given-names></name>, <name><surname>Ebus</surname><given-names>ME</given-names></name>, <name><surname>van Sluis</surname><given-names>P</given-names></name>, <name><surname>Westerhout</surname><given-names>EM</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis</article-title>. <source>Genes Chromosomes Cancer</source>
<volume>51</volume>: <fpage>10</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">22034077</pub-id></mixed-citation></ref><ref id="pone.0079843-Reese1"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Reese</surname><given-names>BE</given-names></name>, <name><surname>Bachman</surname><given-names>KE</given-names></name>, <name><surname>Baylin</surname><given-names>SB</given-names></name>, <name><surname>Rountree</surname><given-names>MR</given-names></name> (<year>2003</year>) <article-title>The methyl-CpG binding protein MBD1 interacts with the p150 subunit of chromatin assembly factor 1</article-title>. <source>Mol Cell Biol</source>
<volume>23</volume>: <fpage>3226</fpage>&#x02013;<lpage>3236</lpage>.<pub-id pub-id-type="pmid">12697822</pub-id></mixed-citation></ref><ref id="pone.0079843-Houlard1"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Houlard</surname><given-names>M</given-names></name>, <name><surname>Berlivet</surname><given-names>S</given-names></name>, <name><surname>Probst</surname><given-names>AV</given-names></name>, <name><surname>Quivy</surname><given-names>JP</given-names></name>, <name><surname>Hery</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>CAF-1 is essential for heterochromatin organization in pluripotent embryonic cells</article-title>. <source>PLoS Genet</source>
<volume>2</volume>: <fpage>e181</fpage>.<pub-id pub-id-type="pmid">17083276</pub-id></mixed-citation></ref><ref id="pone.0079843-Poleshko1"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Poleshko</surname><given-names>A</given-names></name>, <name><surname>Einarson</surname><given-names>MB</given-names></name>, <name><surname>Shalginskikh</surname><given-names>N</given-names></name>, <name><surname>Zhang</surname><given-names>R</given-names></name>, <name><surname>Adams</surname><given-names>PD</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Identification of a functional network of human epigenetic silencing factors</article-title>. <source>J Biol Chem</source>
<volume>285</volume>: <fpage>422</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">19880521</pub-id></mixed-citation></ref><ref id="pone.0079843-Glinsky1"><label>51</label><mixed-citation publication-type="journal">
<name><surname>Glinsky</surname><given-names>GV</given-names></name> (<year>2006</year>) <article-title>Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway</article-title>. <source>Cell Cycle</source>
<volume>5</volume>: <fpage>1208</fpage>&#x02013;<lpage>1216</lpage>.<pub-id pub-id-type="pmid">16760651</pub-id></mixed-citation></ref><ref id="pone.0079843-Jiao1"><label>52</label><mixed-citation publication-type="journal">
<name><surname>Jiao</surname><given-names>R</given-names></name>, <name><surname>Bachrati</surname><given-names>CZ</given-names></name>, <name><surname>Pedrazzi</surname><given-names>G</given-names></name>, <name><surname>Kuster</surname><given-names>P</given-names></name>, <name><surname>Petkovic</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Physical and functional interaction between the Bloom's syndrome gene product and the largest subunit of chromatin assembly factor 1</article-title>. <source>Mol Cell Biol</source>
<volume>24</volume>: <fpage>4710</fpage>&#x02013;<lpage>4719</lpage>.<pub-id pub-id-type="pmid">15143166</pub-id></mixed-citation></ref><ref id="pone.0079843-Bethke1"><label>53</label><mixed-citation publication-type="journal">
<name><surname>Bethke</surname><given-names>L</given-names></name>, <name><surname>Webb</surname><given-names>E</given-names></name>, <name><surname>Murray</surname><given-names>A</given-names></name>, <name><surname>Schoemaker</surname><given-names>M</given-names></name>, <name><surname>Johansen</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma</article-title>. <source>Hum Mol Genet</source>
<volume>17</volume>: <fpage>800</fpage>&#x02013;<lpage>805</lpage>.<pub-id pub-id-type="pmid">18048407</pub-id></mixed-citation></ref><ref id="pone.0079843-VanMaerken2"><label>54</label><mixed-citation publication-type="journal">
<name><surname>Van Maerken</surname><given-names>T</given-names></name>, <name><surname>Rihani</surname><given-names>A</given-names></name>, <name><surname>Dreidax</surname><given-names>D</given-names></name>, <name><surname>De Clercq</surname><given-names>S</given-names></name>, <name><surname>Yigit</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3</article-title>. <source>Mol Cancer Ther</source>
<volume>10</volume>: <fpage>983</fpage>&#x02013;<lpage>993</lpage>.<pub-id pub-id-type="pmid">21460101</pub-id></mixed-citation></ref><ref id="pone.0079843-Kim1"><label>55</label><mixed-citation publication-type="journal">
<name><surname>Kim</surname><given-names>E</given-names></name>, <name><surname>Shohet</surname><given-names>J</given-names></name> (<year>2009</year>) <article-title>Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis</article-title>. <source>J Natl Cancer Inst</source>
<volume>101</volume>: <fpage>1527</fpage>&#x02013;<lpage>1529</lpage>.<pub-id pub-id-type="pmid">19903809</pub-id></mixed-citation></ref><ref id="pone.0079843-Swarbrick1"><label>56</label><mixed-citation publication-type="journal">
<name><surname>Swarbrick</surname><given-names>A</given-names></name>, <name><surname>Woods</surname><given-names>SL</given-names></name>, <name><surname>Shaw</surname><given-names>A</given-names></name>, <name><surname>Balakrishnan</surname><given-names>A</given-names></name>, <name><surname>Phua</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma</article-title>. <source>Nat Med</source>
<volume>16</volume>: <fpage>1134</fpage>&#x02013;<lpage>1140</lpage>.<pub-id pub-id-type="pmid">20871609</pub-id></mixed-citation></ref><ref id="pone.0079843-Maiuri1"><label>57</label><mixed-citation publication-type="journal">
<name><surname>Maiuri</surname><given-names>MC</given-names></name>, <name><surname>Galluzzi</surname><given-names>L</given-names></name>, <name><surname>Morselli</surname><given-names>E</given-names></name>, <name><surname>Kepp</surname><given-names>O</given-names></name>, <name><surname>Malik</surname><given-names>SA</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Autophagy regulation by p53</article-title>. <source>Curr Opin Cell Biol</source>
<volume>22</volume>: <fpage>181</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">20044243</pub-id></mixed-citation></ref><ref id="pone.0079843-Carol1"><label>58</label><mixed-citation publication-type="journal">
<name><surname>Carol</surname><given-names>H</given-names></name>, <name><surname>Reynolds</surname><given-names>CP</given-names></name>, <name><surname>Kang</surname><given-names>MH</given-names></name>, <name><surname>Keir</surname><given-names>ST</given-names></name>, <name><surname>Maris</surname><given-names>JM</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program</article-title>. <source>Pediatr Blood Cancer</source>
<volume>60</volume>: <fpage>633</fpage>&#x02013;<lpage>641</lpage>.<pub-id pub-id-type="pmid">22753001</pub-id></mixed-citation></ref><ref id="pone.0079843-Ding1"><label>59</label><mixed-citation publication-type="journal">
<name><surname>Ding</surname><given-names>Q</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Liu</surname><given-names>JJ</given-names></name>, <name><surname>Jiang</surname><given-names>N</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development</article-title>. <source>J Med Chem</source>.</mixed-citation></ref></ref-list></back></article>